IDT and Sanofi to manufacture mRNA vaccines under development

Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials…

Manufacturing news briefs – stories you might have missed

IDT Australia raises $2 million from shareholders Melbourne pharmaceutical manufacturer IDT Australia has raised $2 million via an over-subscribed share purchase plan to existing shareholders. The raising followed the successful completion of a $5 million placement to professional and sophisticated investors. The total capital raised will be used to fund the company’s capital expenditure programme…

IDT’s strong quarter delivers growth

Pharmaceutical manufacturer IDT Australia is seeing a surge in sales as demand for medical cannabis products rises and companies seek out more capable contract development and manufacturing organisations (CDMO). The Melbourne company told investors that revenues increased for the fourth quarter, with 4QFY23 revenue up 200 percent on the previous corresponding period to $2.4 million.…